Skip to main content

Oncolytic viruses for the treatment of malignant glioma

Publication ,  Journal Article
Merrill, MK; Selznick, LA; Gromeier, M
Published in: Expert Opinion on Therapeutic Patents
March 1, 2006

Malignant glioma is the most common primary malignancy of the human CNS. Despite decades of research, the current therapeutic strategy consists of a multimodal regimen of surgery, chemotherapy and radiation. This course of therapy yields a median survival after diagnosis of ∼ 1 year. This dismal prognosis inspires the ongoing development of novel oncolytic agents targeting glioma, which include gene therapy, immunomodulatory therapy and oncolytic viruses. Oncolytic viruses are defined by their ability to target, replicate in and lyse tumour cells without critically damaging surrounding non-cancerous tissue. Although some viruses are naturally oncolytic and tumour-selective, the advent of modern recombinant DNA technology has allowed the engineering of additional viruses with improved therapeutic indices. This technological advance has enabled rapid growth in the field of viral therapy. Reovirus, Newcastle disease virus (NDV), measles virus, adenovirus, poliovirus and herpes simplex virus-1 are in preclinical and clinical development for use as oncolytic agents against malignant glioma. This report will focus on the recent patent literature in the field of oncolytic viruses for the treatment of malignant glioma. © 2006 Ashley Publications.

Duke Scholars

Published In

Expert Opinion on Therapeutic Patents

DOI

ISSN

1354-3776

Publication Date

March 1, 2006

Volume

16

Issue

3

Start / End Page

363 / 371

Related Subject Headings

  • Medicinal & Biomolecular Chemistry
  • 3214 Pharmacology and pharmaceutical sciences
  • 1115 Pharmacology and Pharmaceutical Sciences
  • 0903 Biomedical Engineering
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Merrill, M. K., Selznick, L. A., & Gromeier, M. (2006). Oncolytic viruses for the treatment of malignant glioma. Expert Opinion on Therapeutic Patents, 16(3), 363–371. https://doi.org/10.1517/13543776.16.3.363
Merrill, M. K., L. A. Selznick, and M. Gromeier. “Oncolytic viruses for the treatment of malignant glioma.” Expert Opinion on Therapeutic Patents 16, no. 3 (March 1, 2006): 363–71. https://doi.org/10.1517/13543776.16.3.363.
Merrill MK, Selznick LA, Gromeier M. Oncolytic viruses for the treatment of malignant glioma. Expert Opinion on Therapeutic Patents. 2006 Mar 1;16(3):363–71.
Merrill, M. K., et al. “Oncolytic viruses for the treatment of malignant glioma.” Expert Opinion on Therapeutic Patents, vol. 16, no. 3, Mar. 2006, pp. 363–71. Scopus, doi:10.1517/13543776.16.3.363.
Merrill MK, Selznick LA, Gromeier M. Oncolytic viruses for the treatment of malignant glioma. Expert Opinion on Therapeutic Patents. 2006 Mar 1;16(3):363–371.

Published In

Expert Opinion on Therapeutic Patents

DOI

ISSN

1354-3776

Publication Date

March 1, 2006

Volume

16

Issue

3

Start / End Page

363 / 371

Related Subject Headings

  • Medicinal & Biomolecular Chemistry
  • 3214 Pharmacology and pharmaceutical sciences
  • 1115 Pharmacology and Pharmaceutical Sciences
  • 0903 Biomedical Engineering